Cidara Therapeutics, Inc. - FORM 10-K - EX-23.1 - CONSENT OF INDEPENDENT PUBLIC ACCOUNTING FIRM - March 15, 2017

Attached files

file filename
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 - Cidara Therapeutics, Inc.exhibit312-10k.htm
EX-32.2 - CERTIFICATION OF CFO PURSUANT TO SARBANES-OXLEY ACT OF 2002 - Cidara Therapeutics, Inc.exhibit322-10k.htm
EX-32.1 - CERTIFICATION OF CEO PURSUANT TO SARBANES-OXLEY ACT OF 2002 - Cidara Therapeutics, Inc.exhibit321-10k.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 - Cidara Therapeutics, Inc.exhibit311-10k.htm
EX-21.1 - LIST OF SUBSIDIARIES - Cidara Therapeutics, Inc.exhibit211-10k.htm
10-K - CIDARA THERAPEUTICS, INC. 2016 FORM 10-K - Cidara Therapeutics, Inc.cdtx10-k2016x12x31.htm


Exhibit 23.1
Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:     
     
     (1)    Registration Statement (Form S-3 No. 333-211472) of Cidara Therapeutics, Inc., and

     (2)    Registration Statements (Form S-8 Nos. 333-203434 and 333-210263) pertaining to the 2013 Stock Option and Grant Plan, the 2015 Equity Inventive Plan, and the 2015 Employee Stock Purchases Plan of Cidara Therapeutics, Inc.;
of our report dated March 15, 2017, with respect to the consolidated financial statements of Cidara Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2016.
/s/ Ernst & Young LLP
San Diego, California
March 15, 2017


Cidara Therapeutics, Inc. Reports